undamentalytics Newsletter
Sign in

Bio-Techne cash flow statement

In fiscal 2026, Bio-Techne's operations generated $292m of cash; it spent $28.9m on capital projects, leaving free cash flow of $263m. It returned $49.9m in dividends and $41.7m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Jun 20102011Jun 20112012Jun 20122013Jun 20132014Jun 20142015Jun 20152016Jun 20162017Jun 20172018Jun 20182019Jun 20192020Jun 20202021Jun 20212022Jun 20222023Jun 20232024Jun 20242025Jun 20252026Jun 2026
Cash from operations111127127124137139144144170182205352325254299288292
Depreciation and amortisation891212193743606478838810110711211097
Stock-based pay112246915283232494239384141
Capital spending5462214201715212552444538633129
Free cash flow107124121101123119127129149156153308280216236257263
Free cash flow after stock pay10612211999119113118114121124121259238177198216222
Dividends paid3840414345474847484849505050505050
Share buybacks15224200——0155043161208027642

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: SHC vs TECHRGEN vs TECHNEO vs TECH

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Bio-Techne's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bio-Techne.